The concern of generic challenges has repeatedly loomed over copyright’s famous drug, Sildenafil, triggering questions about the prospects of connected drug stakes. While first periods saw substantial profits, the patent expiration has allowed the path for discounted copies, likely diminishing earnings and posing a genuine risk for shareholders s